Mutations in Two Genes Encoding Different Subunits of a Receptor Signaling Complex Result in an Identical Disease Phenotype
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as "Nasu-Hakola disease," is a globally distributed recessively inherited disease leading to death during the 5th decade of life and is characterized by early-onset progressive dementia and bone cysts. Elsewhere, we have identified PLOSL mutations in TYROBP (DAP12), which codes for a membrane receptor component in natural-killer and myeloid cells, and also have identified genetic heterogeneity in PLOSL, with some patients carrying no mutations in TYROBP. Here we complete the molecular pathology of PLOSL by identifying TREM2 as the second PLOSL gene. TREM2 forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages and dendritic cells. Patients with PLOSL have no defects in cell-mediated immunity, suggesting a remarkable capacity of the human immune system to compensate for the inactive TYROBP-mediated activation pathway. Our data imply that the TYROBP-mediated signaling pathway plays a significant role in human brain and bone tissue and provide an interesting example of how mutations in two different subunits of a multisubunit receptor complex result in an identical human disease phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Homozygous loss-of-function mutations in TREM2 or DAP12 genes cause Nasu–Hakola disease (NHD), a rare genetic disorder characterized by fatal presenile dementia and bone cysts [38, 39].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [39]
In the citing paper
“TYROBP is a transmembrane adaptor protein for TREM2, SIRPβ1, and CR3 receptors, which are known to be involved in AD pathogenesis [90–92].”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [92]
In the citing paper
“Homozygous Q33X, Y38C and T66M variants have been identified in patients with Nasu-Hakola disease [44, 47, 95].”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“A number of mutations in PLCG2 (about 75%), that have been previously implicated in various inflammatory diseases [92–102], actually map to the autoinhibitory interface on the PLCγ2 model structure and can be considered as pathogenic (Fig. 2c)”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“Even more rare loss-of-function mutations of TREM2 or DAP12 cause a form of recessively inherited presenile dementia, called Nasu-Hakola disease (126, 127).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [126]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bouchon, A., Dietrich, J., & Colonna, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.4991 · Cited by 1,284 · cited 4×
“2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather than in acute, inflammation (Bouchon et al. 2000).”
BackgroundInfluentialTREM-1 amplifies inflammation and is a crucial mediator of septic shock
Bouchon, A., Facchetti, F., Weigand, M. A., & Colonna, M. (2001) · Nature · doi:10.1038/35074114 · Cited by 1,090 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundImmunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 904 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialVitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 748 · cited 1×
“1) (Vitale et al. 1998), MDL1 (chromosome 7q33) (Bakker et al. 1999), CD94 (chromosome 12p13.”
Association of DAP12 with Activating CD94/NKG2C NK Cell Receptors
Lanier, L. L., Corliss, B., Wu, J., & Phillips, J. H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80574-9 · Cited by 559 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialLoss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460 · cited 6×
“Interestingly, patients with PLOSL who are homozygous for mutations in either TREM2 or TYROBP display identical CNS and bone manifestations (table 2)—and no immunological symptoms (Paloneva et al. 2000).”
BackgroundInfluentialSelf-citationBouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundLy-49D and Ly-49H associate with mouse DAP12 and form activating receptors.
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · PubMed · Cited by 277
Cutting Edge: Ly-49D and Ly-49H Associate with Mouse DAP12 and Form Activating Receptors
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.7 · Cited by 249 · cited 1×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundMutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with holoprosencephaly
Ming, J. E., Kaupas, M. E., Roessler, E., Brunner, H. G., Golabi, M., Tekin, M., Stratton, R. F., Sujansky, E., Bale, S. J., & Muenke, M. (2002) · Human Genetics · doi:10.1007/s00439-002-0695-5 · Cited by 244
Research works printed but not linked: 1
- Tranebjærg, 2000, Polycystic lipomembranous osteodysplasia, Tidsskr Nor Laegeforen, 120, 3196
Cited by
Items 501–600 of 694
Bandow, K., Hasegawa, H., Tomomura, M., & Tomomura, A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.045 · Cited by 11
Gray matter lesions in Nasu-Hakola disease: A report on three autopsy cases
Aoki, N., Tsuchiya, K., Togo, T., Kobayashi, Z., Uchikado, H., Katsuse, O., Suzuki, K., Fujishiro, H., Arai, T., Iseki, E., et al. (2010) · Neuropathology · doi:10.1111/j.1440-1789.2010.01152.x · Cited by 12
“DAP12 have been identified as the primary causes of the disease.(5,6) Because microglia have the ability to phagocytose myelin,(15,16) the white matter may be severely damaged by abnormally activated microglia.”
BackgroundLysosomal Storage Disorders and Iron
Brás, J. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-410502-7.00012-0 · Cited by 11
Chen, H., Fan, L., Guo, Q., Wong, M. Y., Zhu, J., Foxe, N. R., Wang, W. T., Nessim, A., Carling, G., Liu, B., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00903-3 · Cited by 10
“Loss-of-function variants in human DAP12 cause Nasu-Hakola disease (NHD), which features cerebral [47–49, 73 ].”
Immunohistochemical characterization of CD33 expression on microglia in Nasu‐Hakola disease brains
Satoh, J., Kino, Y., Motohashi, N., Ishida, T., Yagishita, S., Jinnai, K., Arai, N., Nakamagoe, K., Tamaoka, A., Saito, Y., et al. (2015) · Neuropathology · doi:10.1111/neup.12222 · Cited by 10
“1, which cause the identical phenotype.(7) TREM2, expressed exclusively on myeloid cells, such as osteoclasts, dendritic cells, macrophages and microglia, acts as a receptor for several endogenous ligands, including phosphatidylserine expressed on apoptotic neurons.”
BackgroundFernández‐Vega, I., de Heredia-Goñi, K. P., Santos‐Juanes, J., Goñi-Imízcoz, M., Zaldumbide, L., Zarranz, J. J., & Ferrer, I. (2015) · Histopathology · doi:10.1111/his.12741 · Cited by 14
Lanza, G., Calì, F., Vinci, M., Cosentino, F., Tripodi, M., Spada, R. S., Cantone, M., Bella, R., Mattina, T., & Ferri, R. (2020) · Neural Plasticity · doi:10.1155/2020/8078103 · Cited by 10
“Given the prevalence of this variant in Italy and particularly in the Sicilian population (6/20 alleles, 30%) [22, 29], the occurrence of a “founder effect”might be hypothesized.”
BackgroundInfluentialLok, H. C., & Kwok, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052541 · Cited by 12
Nia, F. H., & Wittamer, V. (2025) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.16317 · Cited by 10
“81,82 Interestingly, various environmental factors can also impact microglia function, potentially leading to neurological disorders.”
Nájera, G. S., Narganes-Carlón, D., & Crowther, D. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-94897-9 · Cited by 13
Bandow, K., Smith, A., & Garlick, J. A. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.10.048 · Cited by 9
Trem2 Enhances Demyelination in the Csf1r+/− Mouse Model of Leukoencephalopathy
Biundo, F., Chiţu, V., Gökhan, Ş., Chen, E., Oppong‐Asare, J., & Stanley, E. R. (2023) · Biomedicines · doi:10.3390/biomedicines11082094 · Cited by 9
Regulation of Osteoclast Activity
Baron, R., & Horne, W. C. (2005) · Springer eBooks · doi:10.1007/1-84628-016-8_3 · Cited by 14
“Rare TREM-2- and DAP12-deficient individuals recently have been identified [133, 134].”
BackgroundBone matrix hypermineralization associated with low bone turnover in a case of Nasu-Hakola disease
Shboul, M., Roschger, P., Ganger, R., Paschalis, L., Rokidi, S. G., Zandieh, S., Behunova, J., Muschitz, C., Fahrleitner‐Pammer, A., Ng, A. Y. J., et al. (2018) · Bone · doi:10.1016/j.bone.2018.10.008 · Cited by 11
“They (2002) also demonstrated mutations in the TREM2 gene in families linked to 6p21-p22 rather than 19q13 [6].”
BackgroundLi, X., Sun, Y., Gong, L., Li, Z., Chen, K., Zhou, Y. F., Gu, Y., Xu, Y., Guo, Q., Hong, Z., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.01.009 · Cited by 11
No evidence for shared etiology in two demyelinative disorders, MS and PLOSL
Sulonen, A.-M., Kallio, S. P., Ellonen, P., Suvela, M. H., Elovaara, I., Koivisto, K. J., Pirttilä, T., Reunanen, M., Tienari, P. J., Palotie, A. V., et al. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.10.005 · Cited by 13
“patients of other populations (Paloneva et al., 2002).”
BackgroundSelf-citationClinical and electrophysiological improvement of adrenomyeloneuropathy with steroid treatment
Zhang, L. X., Bakshi, R., Fine, E., & Moser, H. W. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.822 · Cited by 9
Lee, Y., Jeong, I., Lee, D. W., Seo, Y., Kim, S., & Park, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118094 · Cited by 8
Hu, S., Pan, N., Liu, C., Wang, Y., & Zhang, T. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.775432 · Cited by 8
Schwarz, H., Bässler, S., Balta, D., Socher, E., Zunke, F., & Arnold, P. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113977 · Cited by 8
Maurer‐Morelli, C. V., de Vasconcellos, J. F., Bruxel, E. M., Rocha, C. S., do Canto, A. M., Tedeschi, H., Yasuda, C. L., Cendes, F., & Lopes‐Cendes, Í. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221126666 · Cited by 7
Shaik, A. J., Chepuru, R., Tandra, S., Gaddamanugu, P., Alladi, S., & Kaul, S. (2018) · Neurology India · doi:10.4103/0028-3886.227319 · Cited by 7
Genomics of Alzheimer’s disease
van de Weijer, M. P., Jansen, I. E., Verboven, A. H. A., Andreassen, O. A., & Posthuma, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813176-3.00022-5 · Cited by 7
Translational regulation and protein-coding capacity of the 5′ untranslated region of human TREM2
Yanaizu, M., Adachi, H., Araki, M., Kontani, K., & Kino, Y. (2023) · Communications Biology · doi:10.1038/s42003-023-04998-6 · Cited by 7
“Moreover, homozygous mutations in TREM2 lead to Nasu-Hakola disease, a rare disease characterized by early-onset dementia and bone cysts 7 .”
Targeted sequencing approach to identify genetic mutations in Nasu-Hakola disease
Satoh, J., Yanaizu, M., Tosaki, Y., Sakai, K., & Kino, Y. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01064 · Cited by 10
Palma, A. D., Agresta, A. M., Viglio, S., Rossi, R., D’Amato, M., Silvestre, D. D., Mauri, P., & Iadarola, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189959 · Cited by 8
“The genetic studies on NHD suggest that this disorder is caused by a structural defect of two genes encoding different subunits of the same membrane receptor signalling complex, specifically the DNAX-activating protein 12 (DAP12, also named TYROBP) and the Triggering Receptor Expressed on Myeloid cell 2 (TREM 2) genes…”
BackgroundKinoshita, M., Oyanagi, K., Matsushima, A., Kondo, Y., Hirano, S., Ishizawa, K., Ishihara, K., Terada, S., Inoue, T., Yazawa, I., et al. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123027 · Cited by 6
White matter disorders with cerebral calcification in adulthood
Chelban, V., & Houlden, H. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-99209-1.00024-7 · Cited by 6
Carr, A. J., Hajicek, N., Tsai, A. P., Acharya, P. P., Hardy, P. B., Meyer, E. G., Wyss‐Coray, T., Pearce, K. H., Sondek, J., & Zhang, Q. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108356 · Cited by 6
The late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis
Jocher, G., Müller, S. A., Hsia, H., Osua, M. L., Özcelik, G., Hofmann, L. I., Aßfalg, M., Dinkel, L., Feng, X. M., Schlepckow, K., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202403080 · Cited by 6
Yamazaki, K., Yoshino, Y., Mori, Y., Ochi, S., Yoshida, T., Ishimaru, T., & Ueno, S. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.3.324 · Cited by 6
“324 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2015;13(3):324-326 Copyrightc 2015, Korean College of Neuropsychopharmacology”
BackgroundThe Role of Genetics in Alzheimer's Disease and Parkinson's Disease
Porter, T., Gozt, A., Mastaglia, F. L., & Laws, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch15 · Cited by 6
Swain, P. S., Panda, S., Pati, S., & Dehury, B. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05770-7 · Cited by 6
The Association between TREM2 Gene and Late-Onset Alzheimer’s Disease in Chinese Han Population
Sun, Y., Zhang, Y., Chen, H., & Ren-shou, C. (2021) · Gerontology · doi:10.1159/000517284 · Cited by 6
Novel Signaling Pathways and Therapeutic Targets in Osteoclasts
Takayanagi, H. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72009-8_12 · Cited by 6
[Splenic cyst. Review of the literature and report of 2 cases].
de Melo, V. A., Júnior, A. A., Andrade, L. C., Aragão, J. F. B., & Rosa, J. E. (1995) · PubMed · Cited by 6
Fodder, K., Smith, H. M. G., Yaman, Ü., Piras, I. S., Murthy, M. N., Hardy, J., Lashley, T., de Silva, R., Salih, D. A. M., & Bettencourt, C. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03686-1 · Cited by 5
“For example, genetic variants in the AD associated gene TREM2 are thought to be causative for an adult onset leukodystrophy [20, 21].”
Akinluyi, E. T., Takahashi, K., Connolly, M. G., Poon, W. W., & Macauley, M. S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00805 · Cited by 5
Takahashi, E., Allan, N. P., Peres, R., Ortuğ, A., van der Kouwe, A. J. W., Valli, B., Ethier, E., Levman, J. E. D., Baumer, N., Tsujimura, K., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1023665 · Cited by 5
“Beyond that, mutations in this gene lead to Nasu–Hakola disease, a rare autosomal recessive disorder characterized by bone abnormalities and adult-onset neuropsychiatric features, such as social disinhibition, distractibility, and lack of appropriate emotionality, very similar to common ASD symptoms (Paloneva et al.,…”
BackgroundWilliamson, J. C., & Larner, A. J. (2018) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000271 · Cited by 5
Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer’s disease
Marian, O. C., Tran, C., & Don, A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00023-3 · Cited by 5
Ahmad, S. S., Younis, K., Jeandet, P., Aschner, M., & Khan, H. Z. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210811160007 · Cited by 5
Regional cerebral blood flow in a patient with Nasu-Hakola disease
Takeshita, T., Kaminaga, T., Tatsumi, T., Hatanaka, Y., & Furui, S. (2005) · Annals of Nuclear Medicine · doi:10.1007/bf02984623 · Cited by 5
Possible role of microgliopathy in the pathogenesis of Nasu–Hakola disease
Satoh, J. (2013) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12046 · Cited by 4
“All of these mutations cause an identical disease phenotype.(6,7) The trimolecular complex, composed of TREM2 monomer and DAP12 homodimer, constitutes a receptor/adaptor complex expressed on the cell surface of osteoclasts, dendritic cells (DC), monocytes/ macrophages and microglia (Fig.”
BackgroundMicroglial phagoptosis in development, health, and disease
Li, Y., Chen, S., & Liu, Y. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107211 · Cited by 4
Li, Y., Wang, Y., Li, H., Gao, R., Zhang, W., & Yang, X. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112509 · Cited by 4
Bizzotto, M., You, S. F., Tamborini, M., Faggiani, E., Morini, R., Borreca, A., Zhang, R., Aladyeva, E., Nallapu, A., Ferrari, C., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.043 · Cited by 5
Wang, H., Wen, R., Parker, E., & Yang, L. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03083-9 · Cited by 4
“Loss-of-function mutations affecting the TREM2-TYROBP/DAP12 signaling axis in humans can result in severe neurodegenerative phenotypes characterized by microglial dysfunction, white matter abnormalities, and progressive neurological decline [165–167].”
TREM2 ‐Mediated Myeloid Cells Protect Against Pathological Choroidal Neovascularization
wang, T., Szczepan, M., Gregg, A. T., Wang, X., Smith, L. E. H., & Sun, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202501793r · Cited by 4
“Trem2 haploinsufficiency has been linked to an increased risk for Alzheimer's disease and microglial dysfunction [16], while complete TREM2 loss causes Nasu-Hakola disease [29], an autosomal recessive genetic disorder that affects both the central nervous sys-tem and the skeleton.”
Bibliometric Analysis of TREM2 (2001-2022): Trends, Hotspots and Prospects in Human Disease
Qian, M., Zhong, J., Lu, Z., Zhang, W., Weng, M., Zhang, K., & Jin, Y. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.96851 · Cited by 5
“In the embryonic stages, research on TREM2 began by investigating its role in the pathogenesis of Nasu-Hakola disease, exploring complications like presenile-dementia and bone-cysts [23-26].”
BackgroundTargeting TREM2 signaling shows limited impact on cerebrovascular calcification
Sridhar, S., Zhou, Y., Ibrahim, A., Bertazzo, S., Wyss, T., Swain, A., Maheshwari, U., Huang, S., Colonna, M., & Keller, A. (2024) · Life Science Alliance · doi:10.26508/lsa.202402796 · Cited by 4
“No-tably, patients with loss-of-function mutations in TREM2 also present with brain calci fi cation (Paloneva et al, 2002; Bianchin et al, 2004).”
BackgroundCrockett, A. M., Fuhrmann, M., Garaschuk, O., & Davalos, D. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_5 · Cited by 4
Cagnone, M., Bardoni, A., Iadarola, P., & Viglio, S. (2018) · Microarrays · doi:10.3390/ht7010002 · Cited by 4
“These allowed to observe that the disorder results from the loss-of-function of two genes (TYROBP and TREM2), which encode for different subunits of the same membrane receptor signaling complex that plays a significant role in antigen-specific immune responses by B cells in vivo [20,22,24,25].”
BackgroundMaladies démyélinisantes d’origine génétique
Labauge, P. M., & Boespflug‐Tanguy, O. (2010) · La Presse Médicale · doi:10.1016/j.lpm.2009.11.011 · Cited by 4
Heterozygous TYROBP deletion (PLOSLFIN) is not a strong risk factor for cognitive impairment
Kaivola, K., Jansson, L., Saarentaus, E., Kiviharju, A., Rantalainen, V., Eriksson, J. G., Strandberg, T. E., Polvikoski, T. M., Myllykangas, L., & Tienari, P. J. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.008 · Cited by 5
“…in TYROBP or TREM2 genes cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL, Nasu-Hakola disease) (Paloneva et al., 2000, Paloneva et al., 2002), a rare disease characterized by pathologic fractures, personality changes and presenile dementia (Hakola, 1972).”
Kajikawa, S., Taguchi, Y., Hayata, T., Ezura, Y., Ueta, R., Arimura, S., Inoue, J., Noda, M., & Yamanashi, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.090 · Cited by 4
Luo, W., Chen, H., Fan, L., Guo, Q., Wong, M. Y., Yu, F., Foxe, N. R., Wang, W. T., Nessim, A., Carling, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3454358/v1 · Cited by 4
Chapleau, A., Perrier, S., Durcan, T. M., & Bernard, G. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00533-0 · Cited by 4
Gilani, N., Bitarafan, F., Özaslan, M., Åsheim, S., Heidari, M., & Garshasbi, M. (2024) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2476 · Cited by 3
“In 2002, Paloneva et al. (2002) identified the p.(K186N) variant in a Norwegian family, where two sisters displayed a homozygous substitution, c.558G > T; p.(K186N).”
BackgroundInfluentialEmerging Microglial Therapies and Targets in Clinical Trial
Yan, L., & Crotti, A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_35 · Cited by 3
Parkinson Disease and Autoimmune Disorders—What Can We Learn From Genome-wide Pleiotropy?
McFarland, N. R., McFarland, K. N., & Golde, T. E. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0843 · Cited by 3
Genetik der Alzheimer-Krankheit
Bajaj, T., Ramírez, A., & Wagner-Thelen, H. (2018) · Medizinische Genetik · doi:10.1007/s11825-018-0193-3 · Cited by 4
“Es handelt sich um eine ausgesprochen seltene, autosomalrezessiv vererbte Erkrankung, die sich in einer fortschreitenden Demenz sowie einer polyzystischen Osteodysplasie äußert – Phänotypen, die sich beide mit dysfunktionalen TREM2/TYROBP-exprimierenden Zelltypen, Mikroglia und Osteoklasten, inVerbindungbringen lassen…”
BackgroundChen, D., Zhong, D., Mei, R., Qian, S.-D., Wang, P., Chen, K., & Yu, X. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-022-03465-y · Cited by 3
“[46], meaning TYROBP-mediated signaling pathway played an vital role in human bone tissue.”
BackgroundFamilial cerebral amyloid disorders with prominent white matter involvement
Banerjee, G., Schott, J. M., & Ryan, N. S. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-99209-1.00010-7 · Cited by 3
Human monocyte‐derived microglia‐like ( iMG ) cells: A tool to explore microglial dynamics
Kyuragi, S., Inamine, S., Ohgidani, M., & Kato, T. A. (2024) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12815 · Cited by 3
Mishra, S., Rout, M., Simha, N. L., Dehury, B., & Pati, S. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.126281 · Cited by 3
Ilonen, T., Hakola, P., Vanhanen, M., & Tiihonen, J. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00626.x · Cited by 3
“Surprisingly, the mutation in TREM2 gene can cause clinically entirely similar disease picture as the mutations in the DAP12 (TYROBP ) gene (8).”
BackgroundThe C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation
Solje, E., Hartikainen, P. H., Valori, M., Vanninen, R. L., Tiihonen, J., Hakola, P., Tienari, P. J., & Remes, A. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.149 · Cited by 3
“Mutations in the DNAXactivation protein 12 (DAP12), which is also called the TYRO protein tyrosine kinaseebinding protein (TYROBP), and the triggering receptor expressed on myeloid cells 2 (TREM2) genes are the known genetic causes of NHD (Paloneva et al., 2000, 2002).”
BackgroundNetwork-Based Analysis for Uncovering Mechanisms Underlying Alzheimer’s Disease
Kikuchi, M., Ogishima, S., Mizuno, S., Miyashita, A., Kuwano, R., Nakaya, J., & Tanaka, H. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_29 · Cited by 3
Finnish neuroscience from past to present
Korpi, E. R., Lindholm, D., Panula, P., Tienari, P. J., & Haltia, M. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14693 · Cited by 3
“PLOSL is caused by mutations in the TYROBP and TREM2 genes which both code for components of the same membrane signalling complex (Paloneva et al., 2000, 2002).”
BackgroundArrant, A. E., & Roberson, E. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00006-9 · Cited by 3
Two Genes Behind PLOSL : Molecular and Pathological Characteristics of the Disease
Paloneva, J. (2003) · Työväentutkimus Vuosikirja · Cited by 3
Self-citationZhong, Z., Ulmschneider, M. B., & Lorenz, C. D. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01891 · Cited by 2
Microglial ITAM & ITIM Signaling in Neurodegenerative Disease and Brain Aging
Mangalmurti, A., Bonheur, A., & Lukens, J. R. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169910 · Cited by 2
Gene Mapping and Human Disease
Terwilliger, J. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-95350-8_6 · Cited by 3
Clinical Disorders Associated with Alterations in Bone Resorption
Rubin, J. E., & Nanes, M. S. (2005) · Springer eBooks · doi:10.1007/1-84628-016-8_7 · Cited by 2
“The genetic etiology is a loss-of-function mutation in the gene encoding the TYRO protein tyrosine kinasebinding protein called DAP12, or in some cases a mutation in the TREM2 adaptor [87, 89].”
BackgroundSedel, F. (2007) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(07)32525-6 · Cited by 4
Posterior cortical atrophy: a single case cognitive and radiological follow-up
Esteves, S., Romero, D. A. R., Torralva, T., Cuitiño, M. M., Herndon, S., Couto, B., Ibáñez, A. M., Manes, F. F., & Roca, M. (2018) · Neurocase · doi:10.1080/13554794.2017.1421667 · Cited by 3
Neuroinflammation in Neurological Disorders
Kira, J. (2013) · Advances in neurobiology · doi:10.1007/978-1-4614-8313-7_2 · Cited by 3
TRAPC : A novel Triggering Receptor expressed on Antigen Presenting Cells
van der Holst, R. (2007) · Figshare · Cited by 2
A polarizing answer — microglia in Nasu-Hakola disease
Bennett, M. L. (2023) · Nature Immunology · doi:10.1038/s41590-023-01440-1 · Cited by 2
TREM2 Gene Compound Heterozygosity in Neurodegenerative Disorders
Berdyński, M., Ludwiczak, J., Barczak, A. K., Barcikowska, M., Kuźma‐Kozakiewicz, M., Dunin-Horkawicz, S., Żekanowski, C., & Borzemska, B. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220210 · Cited by 2
“This intronic variant might cause alternative splicing resulting in exon 3 deletion, as has been described previously in patients with the NHD phenotype and c.482+2T>C mutation [7, 50].”
Nasu-Hakola Disease With Stroke-like Attack: A Case Report
Nezhad, A. R., Olfati, N., Shoeibi, A., Talab, F. R., & Sabi, M. S. (2023) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000547 · Cited by 1
Carpanini, S. M., Bradford, B. M., Alfieri, A., Piccardo, P., Monzón‐Sandoval, J., Brown, D., Boyle, A., Pokrovskaya, A., Mabbott, N. A., Manson, J. C., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1525017 · Cited by 2
Pottorf, T. S., Lane, E. L., & Álvarez, F. J. (2025) · Cells · doi:10.3390/cells14191520 · Cited by 1
“Polycystic Lipomembranous Osteodys-plasia with Sclerosing Leukoencephalopathy (PLOSL), also known as Nasu–Hakola disease, is caused by recessive inheritance of homozygous loss-of-function mutations of TREM2 or DAP 12 [80–82].”
Lü, M., Bai, K., Bai, Y., Miao, Y., Zhao, T., Yang, Y., Chen, J., Yang, T., Li, T., & Wei, H. (2025) · Pediatric Discovery · doi:10.1002/pdi3.70024 · Cited by 1
“Early evidence implicating the role of TREM2 in neuropathology was provided from a study on Nasu–Hakola disease (NHD) [31], a rare disorder characterized by progressive, early‐onset dementia.”
Transcriptional Activation of the TREM2 Gene by ZEB2 in a Zinc Finger-Dependent Manner
Yanaizu, M., Takata, Y., Kato, M., Fujiwara, H., & Kino, Y. (2025) · Genes · doi:10.3390/genes16111329 · Cited by 1
“Loss-of-function mutations in TREM2 have long been recognized as the causative factor in Nasu–Hakola disease, a rare hereditary disorder characterized by pathological fractures due to polycystic bone lesions and early-onset dementia associated with leukoencephalopathy [14,15].”
Hirota, Y., Yamamoto, J., Takatori, S., Sakakibara, Y., Takei, K., 佐治多美子, Sekiya, M., Tomita, T., & Iijima, K. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00032-1 · Cited by 1
“Biallelic loss-of-function variants in either TREM2 or TYROBP/DAP12 cause Nasu-Hakola disease, a rare autosomal recessive disorder characterized by early-onset dementia and bone cysts [32, 33].”
Harnessing Microglial Repopulation: From Inflammatory Drivers to Therapeutic Allies in CNS Diseases
Li, G., Liu, H., Lan, Z., Yuan, Y. Z., Li, J. R., Dai, Z., Huang, C., He, C., Qin, S., & Su, Z. (2026) · Glia · doi:10.1002/glia.70169 · Cited by 1
“Patients develop progressive presenile dementia and bone cysts (Paloneva et al. 2000, 2002).”
TREM2 restrains myeloid inflammasome activation to protect against photoreceptor degeneration
wang, T., Su, L., Szczepan, M., Wang, X., Gregg, A. T., Guo, J., Smith, L. E. H., & Sun, Y. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03903-2 · Cited by 1
“…increased risk of Alzheimer’s disease and microglial dysfunction [18], as well as exacerbated laser-induced choroidal neovascularization and vascular leakage [54], whereas complete TREM2 deficiency causes Nasu-Hakola disease [55] and does not affect laser-induced choroidal neovascularization [56].”
Liu, Q., Lin, R., Gao, P.-R., Chen, D.-F., & Li, H. (2026) · Journal of International Medical Research · doi:10.1177/03000605261456056 · Cited by 1
Shirotani, K., Hatta, D., Watanabe, K., Saito, T., Saido, T. C., & Iwata, N. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115894 · Cited by 1
Stephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1
Takahashi, K. (2018) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12479 · Cited by 1
Ferrari, C., Nacmias, B., & Sorbi, S. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_12 · Cited by 1
Disorders of Cellular Trafficking
García‐Cazorla, À., Dionisi‐Vici, C., & Saudubray, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63123-2_44 · Cited by 2
Ikezu, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_30 · Cited by 1
Investigations on molecular aspects of lethal congenital contracture syndrome
Pakkasjärvi, N. A. (2006) · Helda - University of Helsinki Institutional Repository · Cited by 1
Vanhanen, M., Hakola, P., Ilonen, T., & Tiihonen, J. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000346857 · Cited by 1
Génétique et maladies de la substance blanche
Labauge, P. M. (2009) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(09)50908-6 · Cited by 1
Metadata
- Authors
- Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., Tranebjærg, L., Konttinen, Y., & Peltonen, L.
- Affiliations
- University of Helsinki (FI)
- University of California, Los Angeles (US)
- Umeå University (SE)
- University of Washington (US)
- Hospital Universitario La Paz (ES)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Bispebjerg Hospital (DK)
- Helsinki University Hospital (FI)
- Corresponding author
- Peltonen, Leena
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 71
- Issue
- 3
- Pages
- 656-662
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC379202
- OpenAlex
- W2014200126
- Cited by
- 683
- References
- 29
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 27 · 2023: 35 · 2022: 37 · 2021: 48 · 2020: 47 · 2019: 34 · 2018: 54 · 2017: 53 · 2016: 38 · 2015: 42 · 2014: 29 · 2013: 28 · 2012: 11
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3974 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lastentautien Tutkimussäätiö
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Nasu-Hakola disease, TREM2, TYROBP, DAP12, receptor signaling complex, genetic heterogeneity, progressive dementia, bone cysts, recessive inheritance
- MeSH terms
- Triggering Receptor Expressed on Myeloid Cells-1, Actins, Female, Haplotypes, Humans, Male, Membrane Glycoproteins, Membrane Proteins, Molecular Sequence Data, Mutation, Pedigree, Phenotype, Receptors, Immunologic, RNA, Messenger, Signal Transduction, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Protein Subunits, Macromolecular Substances, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.